Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| 8LaBV | 8LaBV6 | U.S. | 1993 | HIV1 | B | Plasma | MMC |
Treatment History
| Order | Regimen | Weeks |
| 1 | NRTI+IDV | 6 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| L10I, I13V, K20R, L63P, E65D |
| >8LaBV6| 25 | codons 1-99 | clone 25 PQITLWQRPVVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD QVPVDICGHKAIGTVLVGPTPVNIIGRDLLTQIGCTLNF >8LaBV6| 26 | codons 1-99 | clone 26 PQITLWQRPIVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD QVPVDICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF >8LaBV6| 28 | codons 1-99 | clone 28 PQITLWQRPIVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD QVPVDICGHKAIGIVLIGPTPVNIIGRNLLTQIGCILNF >8LaBV6| 29 | codons 1-99 | clone 29 PQITLWQRPVVTIKIGGQLKEALLDTGADGTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD QVPVDICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF >8LaBV6| 31 | codons 1-99 | clone 31 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYN QVPVDICGHKAIGTVLVGPTPVNIIGRNLLTQIRCTLNF >8LaBV6| 32 | codons 1-99 | clone 32 PQITLWQRPIVTVKIGGQLREALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD QIPIDICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF >8LaBV6| 33 | codons 1-99 | clone 33 PQITLWQRPVVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD QIPVDICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF >8LaBV6| 35 | codons 1-99 | clone 35 PQITLWQRPIVTVKIGGQLREALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD QIPIDICGHKAIGTVLAGPTPVNIIGRNLLTQIGCTLNF >8LaBV6| codons 1-99 PQITLWQRPIVTVKIGGQLREALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD QIPIDICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF |
References
| Author | Title | Citation |
| Zhang, Y-M | Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. | J Virol, 1997 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |